Dr. Mussa Banisadre, MD

Dr. Banisadre practices at Stockton Hematology Oncology Medical Group, Inc in Stockton, California.

Dr. Banisadre's NPI, 1043264690, was assigned on May 19, 2006. Dr. Banisadre graduated from Shiraz University of Medical Sciences in 1973. Dr. Banisadre holds California license A38740.

Dr. Banisadre's primary practice is Stockton Hematology Oncology Medical Group, Inc, at 2626 N California St, Stockton, CA 95204 in San Joaquin County. The practice phone is (209) 466-2626.

Dr. Banisadre's primary practice is Stockton Hematology Oncology Medical Group, Inc in Stockton, California. Dr. Banisadre is also affiliated with Doctors Medical Center Modesto. The medical group on file is Stockton Hematology Oncology. Dmand AI also links Dr. Banisadre to 3 more hospitals, 1 physician office and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Banisadre practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Banisadre's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Banisadre is licensed in California.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lung cancer, lymphoma, multiple myeloma and purpura and thrombocytopenia among the conditions Dr. Banisadre treats.

CMS data shows 4,540 Medicare services from Dr. Banisadre across 17 procedure codes in 2024, for 293 Medicare patients. Medicare paid $98,136 for them. Every service was in an office.

CMS counts 293 Medicare patients who saw Dr. Banisadre in 2024. The largest group is 65 to 74, with 126 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Banisadre's median patient age at 74, with 68% women.

In 2024, Dr. Banisadre wrote 1,381 Medicare Part D claims for 279 patients. 85% of them were for generic drugs. CMS names the drug for 1,095 of them, across 29 drugs with 11 or more claims each, at $1,685,493 in total drug cost. In 2023, CMS named 1,250 claims across 28 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Banisadre for performance year 2024, reported as part of a group. Dr. Banisadre accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 8 papers to Dr. Banisadre. The most frequent topics are Erythropoietin, Immunoglobulin alpha-Chains and Sheep. Dr. Banisadre has published most often in J Clin Invest. Dr. Banisadre's most frequent co-authors are Farhad Navab, MD, Rolf N. Gulbrandson, MD and George Andrew Sarosi, MD.

CMS Open Payments shows 988 general payments to Dr. Banisadre from 65 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 79% of the total. Novartis Pharmaceuticals Corporation paid the most, $4,920.

Dr. Banisadre graduated from Shiraz University of Medical Sciences in 1973. Dr. Banisadre is a member of ASCO.

Dr. Banisadre is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.